Insider Buying: Enovis (NYSE:ENOV) Insider Purchases $49,946.56 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 2,458 shares of the stock in a transaction on Wednesday, September 2nd. The stock was acquired at an average cost of $20.32 per share, with a total value of $49,946.56. Following the acquisition, the insider owned 56,098 shares of the company’s stock, valued at approximately $1,139,911.36. This represents a 4.58% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Thursday, September 3rd, Oliver Engert acquired 5,140 shares of Enovis stock. The shares were bought at an average price of $19.46 per share, for a total transaction of $100,024.40.
• On Monday, June 15th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was bought at an average price of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average price of $23.00 per share, for a total transaction of $23,000.00.

Enovis Trading Up 0.1%

NYSE ENOV opened at $18.58 on Monday. Enovis Corporation has a 12-month low of $18.52 and a 12-month high of $34.28. The company has a fifty day simple moving average of $25.50 and a two-hundred day simple moving average of $24.22. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock has a market cap of $1.07 billion, a P/E ratio of -0.96 and a beta of 1.31.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period in the previous year, the company earned $0.79 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.

Institutional Investors Weigh In On Enovis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arax Advisory Partners purchased a new position in shares of Enovis during the 4th quarter valued at about $29,000. Allworth Financial LP acquired a new stake in Enovis during the second quarter worth about $36,000. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in Enovis during the second quarter valued at approximately $48,000. Finally, Danske Bank A S acquired a new position in Enovis in the third quarter valued at approximately $64,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of research reports. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. BMO Capital Markets set a $27.00 target price on Enovis in a report on Tuesday, September 1st. BTIG Research dropped their target price on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, September 1st. Canaccord Genuity Group cut their price target on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Finally, Citizens Jmp reduced their price target on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.